Open AccessCurrent recommendations and recent progress in endometrial cancer
Author(s) -
Brooks Rebecca A.,
Fleming Gini F.,
Lastra Ricardo R.,
Lee Nita K.,
Moroney John W.,
Son Christina H.,
Tatebe Ken,
Veneris Jennifer L.
Publication year - 2019
Publication title -
ca: a cancer journal for clinicians
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 62.937
H-Index - 168
eISSN - 1542-4863
pISSN - 0007-9235
DOI - 10.3322/caac.21561
Subject(s) - endometrial cancer , pembrolizumab , medicine , food and drug administration , disease , cancer , incidence (geometry) , clinical trial , oncology , radiation therapy , immunotherapy , microsatellite instability , intensive care medicine , gynecology , biology , pharmacology , physics , optics , allele , biochemistry , gene , microsatellite
Abstract Endometrial cancer is the most common gynecologic cancer in the United States, and its incidence is rising. Although there have been significant recent advances in our understanding of endometrial cancer biology, many aspects of treatment remain mired in controversy, including the role of surgical lymph node assessment and the selection of patients for adjuvant radiation or chemotherapy. For the subset of women with microsatellite‐instable, metastatic disease, anti– programmed cell death protein 1 immunotherapy (pembrolizumab) is now approved by the US Food and Drug Administration, and numerous trials are attempting to build on this early success.